Ian Martinez, MD
Gastroenterology · Arecibo, PRNPI 1376734962
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.9% of the total. 2025 is the largest year on record at $1,362, 2.7 times the $504 reported in 2019.
Across 235 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$598
- Takeda Pharmaceuticals U.S.A., Inc.$500
- Phathom Pharmaceuticals, Inc.$419
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$354
- Madrigal Pharmaceuticals$227
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,55698%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,439 |
| Johnson & Johnson | 32 | $598 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $500 |
| Phathom Pharmaceuticals, Inc. | 3 | $419 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $354 |
| Madrigal Pharmaceuticals | 9 | $227 |
| Pfizer | 11 | $215 |
| Ardelyx, Inc. | 7 | $130 |
| Intercept Pharmaceuticals, Inc. | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Evoke Pharma, Inc. | 4 | $75 |
| Merck | 4 | $72 |
| Lilly USA, LLC | 3 | $54 |
| Bristol Myers Squibb | 2 | $49 |
| Braintree Laboratories, Inc. | 2 | $39 |
| Vivus LLC | 2 | $38 |
| Gilead | 3 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Novo Nordisk | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Boston Scientific | 1 | $21 |
| Sanofi | 1 | $20 |
| Echosens North America, Inc. | 1 | $19 |
| Conmed Corporation | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$419
How this compares
$4,653 in reported general payments places this provider in the 75th percentile of 198 gastroenterology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 12 | $76,476 |
| LinzessLinaclotide | 26 | $40,906 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 13 | $2,235 |
| Omeprazole | 168 | $2,154 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 57 | $1,435 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,203 |
| Pantoprazole Sodium | 115 | $975 |
| Famotidine | 49 | $842 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $446 |
| Dicyclomine Hcl | 31 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Linzess | $1,439 | $117,38238 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $32 | $2,23513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 198 gastroenterology providers in Puerto Rico.
Other gastroenterology in Arecibo
- Rene Rocha RodriguezArecibo$6K
- Carlos Laboy OlivieriArecibo$4K
- Ahmed Morales JorgeCoto Laurel$214K
- Barbara Rosado CarrionPonce$176K
- Rafael Pastrana LabordeHato Rey$76K
- Miguel de Varona-NegronCaguas$68K
- Marcia Cruz CorreaSan Juan$62K
- Francisco CebolleroMayaguez$52K
- Loscar SantiagoSan Juan$39K
- Henry Gonzalez RiveraSan Juan$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.